

October 14, 2015



## Matinas BioPharma to Present at the 14th Annual BIO Investor Forum on October 20, 2015

**Presentation With Live Webcast on Tuesday, Oct. 20 at 11:00 a.m. PDT / 2:00 p.m. EDT**

BEDMINSTER, N.J., Oct. 14, 2015 (GLOBE NEWSWIRE) -- [Matinas BioPharma Holdings, Inc.](#) (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it will be presenting at the [14<sup>th</sup> Annual BIO Investor Forum](#) being held October 20-21, 2015, at the Parc 55 in San Francisco, California.

Jerome D. Jabbour, Co-Founder and Chief Business Officer, will present on Tuesday, Oct. 20, 2015, at 11:00 a.m. PDT (2:00 p.m. EDT).

As part of his presentation, Mr. Jabbour will provide an update on the NIH/NIAID-funded Phase 2a clinical study of the Company's lead drug candidate [MAT2203](#), an orally-administered, encochleated formulation of the broad spectrum fungicidal medication amphotericin B. The Company recently received [approval from the Institutional Review Board \(IRB\) of the National Institutes of Health \(NIH\) for the MAT2203 study and patient enrollment is expected to commence in the fourth quarter of 2015.](#)

Mr. Jabbour will also discuss the Company's development plans for [MAT2501](#), an orally administered, encochleated formulation of the broad spectrum aminoglycoside antibiotic amikacin to treat gram-negative bacterial infections and intracellular bacterial infections.

A live audio webcast of the presentation will be available on the Company's website ([www.matinasbiopharma.com](http://www.matinasbiopharma.com)) in the [Investor Relations](#) section of the [Events](#) page. The webcast will be available approximately two hours after the presentation ends and will be accessible for one month.

### About BIO

[BIO](#) is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. The 14<sup>th</sup> Annual [BIO Investor Forum](#) is an international biotech investor conference focused on early and established private companies as well as emerging public companies. BIO also produces the [BIO International Convention](#), the world's largest

gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

## About Matinas BioPharma

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections. The Company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. The Company's lead drug candidate is MAT2203, an orally-administered, encochleated formulation of amphotericin B (a broad spectrum fungicidal agent). The Company also intends to file an investigational new drug application (IND) for MAT2501, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for gram-negative and intracellular bacterial infections. In addition, the Company is exploring development and partnership options for MAT9001, a prescription-only omega-3 fatty acid-based composition under development for hypertriglyceridemia, which has shown superiority versus Vascepa<sup>®</sup> (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoproteins and PCSK9 levels.

The Company's lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulation technology.

For more information, please visit [www.matinasbiopharma.com](http://www.matinasbiopharma.com) and connect with the Company on [Twitter](#), [LinkedIn](#), [Facebook](#), and [Google+](#).

**Forward Looking Statements:** *This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's strategic focus and the future development of its product candidates, including MAT2203, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the Company's ability to identify and pursue development and partnership opportunities for its MAT9001 on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to maintain and derive benefit from the Qualified Infectious Disease Product (QIDP) and Fast Track designations for MAT2203, which does not change the standards for regulatory approval or guarantee regulatory approval on an expedited basis, or at all; our ability to*

*protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.*

Investor Contact

Jenene Thomas

Jenene Thomas Communications, LLC

Phone: +1 (908) 938-1475

Email: [jthomas@matinasbiopharma.com](mailto:jthomas@matinasbiopharma.com)

Media Contact:

David Connolly

LaVoieHealthScience

Phone: +1 (617) 374-8800

Email: [dconnolly@lavoiehealthscience.com](mailto:dconnolly@lavoiehealthscience.com)



Source: Matinas BioPharma Holdings, Inc.